

Julien Mendlewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5330079/publications.pdf>

Version: 2024-02-01

31
papers

872
citations

567281

15
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1474
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	4.1	3
2	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
3	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
4	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	2.0	2
5	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
6	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	4.1	18
7	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	4.8	17
8	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1
9	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
10	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	2.1	2
11	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14
12	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
13	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	4.8	20
14	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.7	18
15	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	2.8	44
16	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	28
17	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.7	47
18	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: <scp>5-HTTLPR</scp> and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.7	15
20	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	2.2	76
21	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017, 91, 1-13.	3.1	77
22	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017, 27, 625-632.	0.7	19
23	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 782-787.	2.1	10
24	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 215-222.	2.2	73
25	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.7	50
26	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.7	77
27	European Group for the Study of Resistant Depression (GSRD) – Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.7	111
28	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , 2012, 53, 24-38.	3.1	34
29	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 297-301.	1.7	18
30	Towards achieving remission in the treatment of depression. <i>Dialogues in Clinical Neuroscience</i> , 2008, 10, 371-375.	3.7	27
31	Genetic refinement and physical mapping of a chromosome 18q candidate region for bipolar disorder. <i>European Journal of Human Genetics</i> , 1999, 7, 427-434.	2.8	19